“A Randomized, Double-Blind, Multicenter Study to Compare the Efficacy, Safety, and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) With Originator Adalimumab in Patients With Moderate-to-Severe Chronic Plaque Psoriasis”. SKIN The Journal of Cutaneous Medicine 1, no. 3.1 (October 27, 2017): s29. Accessed May 1, 2026. https://skin.dermsquared.com/skin/article/view/202.